When Compounding Meets Compression - A Mid-Term Short on CoStar (CSGP)
CoStar looks like a compounding machine on paper but the market is pricing a mismatch between growth talk and cash reality. With EPS near zero, free cash flow of only $41M, and an EV/EBITDA north of 76x, I'm laying out a mid-term short: entry $36.50, initial target $28.00, stop $40.50. This trade bets that lofty 2026 expectations and a $1.5B buybac…